Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1974 participants.

Also called NCT02207634

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose other
Phase
Phase 3
Enrolled
  • 1,974 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02207634
  • EudraCT 2014-001976-75
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Slovakia, South Africa, Spain, Sweden, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02207634. Randomized; quadruple masking; primary purpose other. Start 2014-09-10 (actual); primary completion 2016-11-11 (actual). Results posted on 2018-01-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Acronym
EBBINGHAUS
Condition
Dyslipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Placebo
Intervention (Drug)
Background Statin Therapy
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02207634
Content hash
5b4e735447acdd435da0e3fa769048c6f097c9f6454de2e458b4af183e9c876a